Revolutionary New Treatment for Chronic Graft-versus-Host Disease Unveiled
The FDA has approved Niktimvo for treating chronic graft-versus-host disease (GVHD) in adults and children weighing over 40 kg....
Jon Napitupulu
Tivic Health Reports Phase 1 VNS Success
Tivic Health, a bioelectronic medicine company, announced its financial results for the second quarter of 2024, highlighting its commitment...
PPD Recognized for Clinical Digital Services Leadership
The PPD clinical research arm of Thermo Fisher Scientific has consistently been acknowledged as an industry leader in digital...
Gilead’s Livdelzi (Seladelpar) Approved for PBC by US FDA
The U.S. Food and Drug Administration (FDA) has approved Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC), an autoimmune...
Virocell Biologics: Funding Success Despite Market Challenges
ViroCell Biologics, a specialized CDMO in GMP viral vector manufacturing, has successfully closed an oversubscribed convertible note offering to...
New Medable Studio Gives Sponsors Unmatched Control in eCOA Trials
Medable introduces Medable Studio, a revolutionary application that simplifies and accelerates the process of configuring, translating, and launching eClinical...
Anti-TIGIT Antibody: The Revolutionary Cancer Treatment You Must Know About
Anti-TIGIT antibodies are revolutionizing cancer treatment by targeting the immune inhibitory receptor TIGIT, expressed on T cells and NK...
Cybin’s Breakthrough Therapy for Major Depressive Disorder: A Game-Changer in Mental Health
Cybin, a neuropsychiatry company, recently held a successful meeting with the FDA regarding its Type B Breakthrough Therapy for...
NorthStar and Convergent Expand Collaboration on Conv01-α
NorthStar Medical Radioisotopes and Convergent Therapeutics have inked a contract for manufacturing services, collaborating on CONV01-α, targeted radiotherapy for...
Report Predicts $11.9B Surge in eClinical Solutions Market Driven by Clinical Trial and EHR Adoption
The global market for eClinical solutions, which streamline clinical trials, is projected to expand rapidly, reaching $21.9 billion by...